A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
← catalyst calendarNCT05689151 · readout in 499 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
183estimated
Sites
30
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-09 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis
- Eczema
Intervention
- Drug: Abrocitinib
Primary outcome
what the primary-completion date above is the date OFProportion of patients with an Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) (on a 5- point scale) and a reduction from baseline of ≥2 points
measured 16 weeks
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed